Desjardins Global Asset Management Inc. Biomarin Pharmaceutical Inc Transaction History
Desjardins Global Asset Management Inc.
- $922 Million
- Q4 2023
A detailed history of Desjardins Global Asset Management Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Desjardins Global Asset Management Inc. holds 1,256 shares of BMRN stock, worth $102,301. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,256
Previous 1,312
4.27%
Holding current value
$102,301
Previous $116,000
4.31%
% of portfolio
0.01%
Previous 0.01%
Shares
9 transactions
Others Institutions Holding BMRN
# of Institutions
623Shares Held
181MCall Options Held
1.73MPut Options Held
1.73M-
Primecap Management CO Pasadena, CA18.7MShares$1.52 Billion1.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.1MShares$1.48 Billion0.03% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$1.18 Billion0.03% of portfolio
-
Dodge & Cox San Francisco, CA14MShares$1.14 Billion0.75% of portfolio
-
State Street Corp Boston, MA6.9MShares$562 Million0.03% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $15.1B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...